Sumitra Thongprasert

23.8k total citations · 8 hit papers
91 papers, 18.3k citations indexed

About

Sumitra Thongprasert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sumitra Thongprasert has authored 91 papers receiving a total of 18.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 16 papers in Molecular Biology. Recurrent topics in Sumitra Thongprasert's work include Lung Cancer Treatments and Mutations (57 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Research Studies (21 papers). Sumitra Thongprasert is often cited by papers focused on Lung Cancer Treatments and Mutations (57 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Research Studies (21 papers). Sumitra Thongprasert collaborates with scholars based in Thailand, China and Taiwan. Sumitra Thongprasert's co-authors include James Chih‐Hsin Yang, Yi‐Long Wu, Tony Mok, Masahiro Fukuoka, Patrapim Sunpaweravong, Nagahiro Saijo, Alison Armour, Emma Duffield, Haiyi Jiang and José Rodrigues Pereira and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Sumitra Thongprasert

87 papers receiving 17.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 6.4k citations Tony Mok, Yi‐Long Wu et al. profile →
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 4.3k citations Eng Huat Tan, Sumitra Thongprasert et al. profile →
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 1.7k citations Nick Thatcher, Alex Y. Chang et al. profile →
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

2011 1.2k citations Masahiro Fukuoka, Yi‐Long Wu et al. profile →
A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

2014 1.1k citations Sumitra Thongprasert et al. Journal of Thoracic Oncology profile →
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

2013 383 citations Sumitra Thongprasert, Eng Huat Tan et al. profile →
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

2015 367 citations Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research profile →
Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia

2013 366 citations Ho Yeong Lim, Sumitra Thongprasert et al. profile →

Peers

Sumitra Thongprasert

PRM

ONCOL

SURGE

Silvia Novello Italy

Sai‐Hong Ignatius Ou United States

Filippo de Marinis Italy

Lucio Crinò Italy

Vera Hirsh Canada

Tudor–Eliade Ciuleanu Romania

Alan Sandler United States

Johan Vansteenkiste Belgium

Byoung Chul Cho South Korea

Lesley Seymour Canada

Silvia Novello Italy

Sumitra Thongprasert

13.0k ×0.9

PRM

11.6k ×0.9

ONCOL

5.0k ×1.1

3.6k ×1.0

1.5k ×1.1

SURGE

Citations per year, relative to Sumitra Thongprasert Sumitra Thongprasert (= 1×) peers Silvia Novello

Countries citing papers authored by Sumitra Thongprasert

Since Specialization

Citations

This map shows the geographic impact of Sumitra Thongprasert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumitra Thongprasert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumitra Thongprasert more than expected).

Fields of papers citing papers by Sumitra Thongprasert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumitra Thongprasert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumitra Thongprasert. The network helps show where Sumitra Thongprasert may publish in the future.

Co-authorship network of co-authors of Sumitra Thongprasert

This figure shows the co-authorship network connecting the top 25 collaborators of Sumitra Thongprasert. A scholar is included among the top collaborators of Sumitra Thongprasert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumitra Thongprasert. Sumitra Thongprasert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Permsuwan, Unchalee, et al.. (2019). Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand. Value in Health Regional Issues. 21. 9–16. 4 indexed citations

Thongprasert, Sumitra, et al.. (2018). 157P Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: A phase IV study. Journal of Thoracic Oncology. 13(4). S94–S94.

Wu, Yi‐Long, Nagahiro Saijo, Sumitra Thongprasert, et al.. (2016). Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 104. 119–125. 40 indexed citations

Mok, Tony, Yi‐Long Wu, Jin Soo Lee, et al.. (2015). Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clinical Cancer Research. 21(14). 3196–3203. 367 indexed citations breakdown →

Vansteenkiste, Johan, Jean‐Luc Canon, Filippo de Braud, et al.. (2015). Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 10(9). 1319–1327. 123 indexed citations

Thongprasert, Sumitra, et al.. (2015). WILLINGNESS TO PAY FOR LUNG CANCER TREATMENT: PATIENT VERSUS GENERAL PUBLIC VALUES. International Journal of Technology Assessment in Health Care. 31(4). 264–270. 9 indexed citations

Thongprasert, Sumitra, et al.. (2012). Cost‐utility and budget impact analyses of gefitinib in second‐line treatment for advanced non‐small cell lung cancer from Thai payer perspective. Asia-Pacific Journal of Clinical Oncology. 8(1). 53–61. 14 indexed citations

Thongprasert, Sumitra, Unchalee Permsuwan, Chidchanok Ruengorn, Chaiyut Charoentum, & Busyamas Chewaskulyong. (2011). Cost‐effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non‐small cell lung cancer. Asia-Pacific Journal of Clinical Oncology. 7(4). 369–375. 6 indexed citations

Yi, Jun, Sumitra Thongprasert, Yong‐Seok Jee, et al.. (2011). A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study. European Journal of Cancer. 48(2). 196–201. 101 indexed citations

10.

Pas, Tommaso De, Joo-Hang Kim, Paul Zarogoulidis, et al.. (2009). MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized. Journal of Thoracic Oncology. 4(9). 2 indexed citations

11.

Thongprasert, Sumitra, et al.. (2006). A phase II study of docetaxel and carboplatin in Thai patients with advanced non-small-cell lung cancer.. PubMed. 89(2). 152–9. 5 indexed citations

12.

Chang, Alex Y., Purvish M. Parikh, Sumitra Thongprasert, et al.. (2006). Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study. Journal of Thoracic Oncology. 1(8). 847–855. 144 indexed citations

13.

Thongprasert, Sumitra, et al.. (2005). Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Annals of Oncology. 16(2). 279–281. 120 indexed citations

14.

Thongprasert, Sumitra. (2005). The role of chemotherapy in cholangiocarcinoma. Annals of Oncology. 16. ii93–ii96. 129 indexed citations

15.

Thongprasert, Sumitra, et al.. (2004). Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients.. PubMed. 87(4). 367–71. 4 indexed citations

16.

Louthrenoo, Worawit, et al.. (2003). Kaposi[apos ]s sarcoma in rheumatic diseases. Seminars in Arthritis and Rheumatism. 32(5). 326–333. 15 indexed citations

17.

Thongprasert, Sumitra, et al.. (2001). Protective effects of fosfomycin on cisplatin- induced nephrotoxicity in patients with lung cancer. International Journal of Clinical Pharmacology and Therapeutics. 39(3). 121–125. 5 indexed citations

18.

Thongprasert, Sumitra. (2000). Efficacy and Tolerability of Tropisetron in the Prevention of Cisplatin-induced Nausea and Vomiting in Advanced Non-small Cell Lung Cancer. Acta Oncologica. 39(2). 221–224. 4 indexed citations

19.

Thongprasert, Sumitra. (1999). Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 24(1). 17–24. 117 indexed citations

20.

Chua, Daniel T. T., Jonathan S. T. Sham, Damon Choy, et al.. (1998). Preliminary report of the asian-oceanian clinical oncology association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 83(11). 2270–2283. 226 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact